author-photo

Paul P. Tak

University of Amsterdam
GlaxoSmithKline
University of Cambridge

134

Papers

9695

Citations

Citation Trend

Filter By

Papers (134) Sort By

Journal Conference Others

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

2021 BMJ Open Gastroenterology
Show All
- Source
- Cite
- Save
Citations (1)
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.

2021 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (7)
Targeting GM-CSF in rheumatological conditions: risk of PAP – Authors' reply

2021
Show All
- Source
- Cite
- Save
Citations (0)
MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study

2020
Show All
- Source
- Cite
- Save
Citations (4)
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial

2020
Show All
- Source
- Cite
- Save
Citations (3)
Novel Insights into Rheumatoid Arthritis Through Characterisation of Concordant Changes in DNA Methylation and Gene Expression in Synovial Biopsies of Patients with Differing Numbers of Swollen Joints

2020 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

2020
Show All
- Source
- Cite
- Save
Citations (8)
cDC1 are required for the initiation of collagen-induced arthritis

2020
Show All
- Source
- Cite
- Save
Citations (1)
OP0228 GSK3196165 AN INVESTIGATIONAL ANTI-GM-CSF MONOCLONAL ANTIBODY, IMPROVES PATIENT REPORTED OUTCOMES IN A PHASE IIB STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

2019 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (2)
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

2019 BMJ Open
Show All
- Source
- Cite
- Save
Citations (43)